Fluticasone furoate/vilanterol dry-powder inhaler: a guide to its use in chronic obstructive pulmonary disease

Abstract The fixed combination of the corticosteroid fluticasone furoate with the long-acting β2-adrenergic agonist vilanterol is an effective and generally well tolerated inhalation agent for the treatment of chronic obstructive pulmonary disease (COPD). Fluticasone furoate/vilanterol (Relvar®, Breo®, Revinty®) inhaled once daily via a dry-powder inhaler (Ellipta®) provided rapid and sustained improvements in pulmonary function, which were at least as good as those achieved with twice-daily fluticasone propionate/salmeterol and, over the long term, reduced exacerbation rates in clinical trials in patients with moderate to very severe COPD. The added convenience of once- versus twice-daily administration may improve treatment adherence in some patients.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research